Cargando…

Preclinical Modeling for Therapeutic Development in Cystic Fibrosis

Detalles Bibliográficos
Autor principal:	Bonfield, Tracey L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999106/ https://www.ncbi.nlm.nih.gov/pubmed/31697560 http://dx.doi.org/10.1164/rccm.201910-2056ED

Ejemplares similares

Enhancing Cystic Fibrosis Immune Regulation
por: van Heeckeren, Anna M., et al.
Publicado: (2021)

Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model
por: Lu, Shiping, et al.
Publicado: (2021)

Editorial: Special Issue on “Therapeutic Approaches for Cystic Fibrosis”
por: Pedemonte, Nicoletta
Publicado: (2020)

Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells
por: Saadane, Aicha, et al.
Publicado: (2011)

Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment
por: Sutton, Morgan T., et al.
Publicado: (2016)

Membrane Lipids and CFTR: The Yin/Yang of Efficient Ceramide Metabolism
por: Bonfield, Tracey L.
Publicado: (2020)

Cystic Fibrosis Mice Develop Spontaneous Chronic Bordetella Airway Infections
por: Darrah, R, et al.
Publicado: (2017)

New Developments in Cystic Fibrosis Airway Inflammation
por: Palaniyar, Nades, et al.
Publicado: (2015)

Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis
por: Silva, Iris A. L., et al.
Publicado: (2022)

Cystic fibrosis revisited
por: Kulkarni, H, et al.
Publicado: (2019)

Cystic Fibrosis Screen Positive, Inconclusive Diagnosis Genotypes in the Cystic Fibrosis Registry
por: Thompson, Cassandra, et al.
Publicado: (2023)

Re-thinking the preclinical development of GBM therapeutics
por: Cosset, Érika, et al.
Publicado: (2018)

Clinical Advances in Cystic Fibrosis
por: Imperlini, Esther, et al.
Publicado: (2022)

Cystic Fibrosis: “Ionocyte Modulators”?
por: Shah, Viral S., et al.
Publicado: (2023)

The treatment burden of cystic fibrosis: a day-to-day experience with treatment as someone with cystic fibrosis
por: Maetz, Jessica, et al.
Publicado: (2021)

Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing
por: Hoppe, Jordana E., et al.
Publicado: (2022)

A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants
por: Wainwright, Claire E.
Publicado: (2022)

Comparing cystic fibrosis outcomes across the pond
por: Taylor-Robinson, David C, et al.
Publicado: (2015)

Cystic fibrosis in Brazil: achievements in survival
por: Vendrusculo, Fernanda Maria, et al.
Publicado: (2021)

The Impact of COVID-19 in Cystic Fibrosis
por: Flume, Patrick A., et al.
Publicado: (2022)

Rats Race to Keep Pace in the Growing Cystic Fibrosis Model Space
por: Hisert, Katherine B.
Publicado: (2020)

The Future of Highly Effective Modulator Therapy in Cystic Fibrosis
por: Daines, Cori L., et al.
Publicado: (2021)

Steps toward Cell Therapy for Cystic Fibrosis
por: Koh, Kyung Duk, et al.
Publicado: (2020)

Cystic fibrosis-related diabetes: The unmet need
por: Pozo, Leonardo, et al.
Publicado: (2020)

Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Cystic Fibrosis Inflammation: Hyperinflammatory, Hypoinflammatory, or Both?
por: Murphy, Sean V., et al.
Publicado: (2019)

Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021)

Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
por: Liu, Zhongyu, et al.
Publicado: (2020)

Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives
por: Kim, Young Jin, et al.
Publicado: (2023)

Is PI3K a Villain in Cystic Fibrosis?
por: Natarajan, Viswanathan
Publicado: (2020)

Nutrition in Cystic Fibrosis: as important as the management of pulmonary disease
por: Adde, Fabíola Villac
Publicado: (2015)

Airway Inflammatory/Immune Responses in COPD and Cystic Fibrosis
por: De Rose, Virginia, et al.
Publicado: (2018)

Shifting Landscape of Airway Infection in Early Cystic Fibrosis
por: Hoppe, Jordana E., et al.
Publicado: (2019)

Infection and Inflammation MUC up the Cystic Fibrosis Airway
por: Ma, Jonathan
Publicado: (2022)

Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development
por: Auster, Lauren, et al.
Publicado: (2019)

Why Do We Screen Newborn Infants for Cystic Fibrosis?
por: Barben, Jürg, et al.
Publicado: (2020)

Combination Therapy with Lumacaftor–Ivacaftor in Cystic Fibrosis. Keeping It Real
por: Sala, Marc A., et al.
Publicado: (2020)

Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association?
por: Nichols, Dave P., et al.
Publicado: (2020)

Airway Surface Liquid and Impaired Antiviral Defense in Cystic Fibrosis
por: Voynow, Judith A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7asgoktl8qjmfsrrmfpecp8t84